Skip to main content
. Author manuscript; available in PMC: 2022 Aug 9.
Published in final edited form as: Adv Drug Deliv Rev. 2022 Jan 24;182:114116. doi: 10.1016/j.addr.2022.114116

Fig. 3. Literature analysis of monocyte and/or macrophage targeted nanoparticles in CVDs.

Fig. 3.

Using the search parameters from the monocyte targeting group shown in (Fig. 2), the studies were further categorized by nanoparticle composition types. The literature was searched with respect to the following categories A) All CVDs, B) Atherosclerosis, C) Diabetes, and D) HIV. Notable nanoparticle delivery schemes were listed for each disease scheme to denote unique trends found in the literature. Review papers were excluded from this analysis.